Company news
Dyne Therapeutics, Inc. news in 2024
Dyne Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 11, 2024
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
October 8, 2024
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 22, 2024
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
September 2, 2024
Dyne Therapeutics Announces Key Leadership Appointments
September 2, 2024
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 11, 2024
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
June 23, 2024
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
June 12, 2024
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
May 29, 2024
Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock
May 20, 2024
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
May 19, 2024
Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8: 00 a.m. ET
May 18, 2024
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 1, 2024
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
March 26, 2024
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
March 26, 2024
Dyne Therapeutics Announces CEO Transition
March 24, 2024
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
March 12, 2024
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 4, 2024
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
February 13, 2024
Dyne Therapeutics to Present at February Investor Conferences
January 31, 2024
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
January 3, 2024
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
January 2, 2024
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8: 00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
January 1, 2024
Decks in 2024
- Technical Presentation (September 2024)
Technical · 26 slides · Sep 3, 2024
- Corporate Update (May 2024)
Corporate update · 47 slides · May 20, 2024
- 2024 AAN Annual Meeting
Conference · 11 slides · Apr 15, 2024